Search This Blog

Friday, March 1, 2019

Bayer’s sorafenib granted FDA orphan designation

Bayer HealthCare Pharmaceuticals’ sorafenib was granted FDA orphan designation as a treatment of desmoid tumors/aggressive fibromatosis, according to a post to the agency’s website
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)